All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
YM Biosciences Inc. has enjoyed a sustained boost to its stock value since reporting positive Phase I/II results for JAK/JAK2 kinase inhibitor CYT387 in December 2011.